

Is healthcare the smartest place to put your money right now?

UK healthcare investment just hit a record high. Institutional investors are moving fast. This briefing explains why – and introduces one company you haven't heard of yet, but should.

Swipe to find out →

£12 billion deployed into UK healthcare in 2025. The highest on record.

£12bn+

UK healthcare investment 2025

4x

Five-year prior average

280

M&A deals completed in 2025

92%

Healthcare businesses confident about future prosperity

When institutional capital moves at that scale, sophisticated investors take notice.

Healthcare doesn't just grow. It endures.

Unlike consumer sectors, healthcare demand is driven by demographics – not sentiment. Three forces make it structurally different from every other sector:

Ageing population. Demand for healthcare services rises regardless of economic conditions.

NHS pressure. A system under strain creates opportunity for private-sector innovation.

Diagnostics boom. NHS backlogs are accelerating investor interest in devices and diagnostics.

"Healthcare continues to stand apart from other sectors, supported by long-term demographic tailwinds and predictable demand." – Heligan Group, 2026

Medical devices: the quiet growth story of UK healthcare M&A

Unlike in 2025, medical equipment and devices represented 17% of all UK healthcare deals.

Diagnostics led the way – driven by NHS backlogs, rising chronic disease, and the rollout of Community Diagnostic Centres.

The most compelling opportunities sit at the intersection of:

Clinical need

Proven technology

Scalable IP

What follows is exactly that.

Catheters have existed for 3,000 years. The Foley – still the standard today – was invented 91 years ago. Nothing meaningful has changed since

From ancient reed tubes to the Foley catheter introduced in 1935, urinary catheterisation has remained fundamentally unchanged. It is uncomfortable, infection-prone, and humiliating for patients.

Ingenion Medical has CE Mark authorisation for the **cymactive™ 2.0R** – a patented, patient-controlled indwelling catheter that uses an external magnet to mimic natural urination. No external bag. No multiple daily insertions. Just dignity restored.

15–25% of hospitalised patients have a urinary catheter. Most are still using a device invented in the 20th century

\$5.5bn

Global urinary catheter market
(2023)

15-25%

Hospitalised patients with a catheter in Europe

£175m

NHS annual catheter spend

30 days

cymactive™ CE approved in-dwelling duration

Catheter-Associated Urinary Tract Infections (CAUTIs) cost the NHS billions annually. **cymactive™** is designed to dramatically reduce them

CE marked. NHS trials underway. Now raising up to £2 million in equity.

This is not a concept. This is a commercial-stage medical device company with:

- ✓ **CE Mark for cymactive™ 2.0R** under the EU MDR
- ✓ **NHS randomised controlled trial (ACCTUATE)** comparing **cymactive™** vs Foley over 90 days
- ✓ **Innovate UK grants** – awarded four rounds of government funding
- ✓ **Equity raise** – up to £2 million, open to Sophisticated and HNW Investors
- ✓ **Pipeline technology** – core valve IP extends into female incontinence and retention

What leading clinicians say about cymactive™

"There is a significant unmet need for men relating to intervention following urinary retention.

Potentially, this device will prove to be a very effective alternative solution." – Chris Chapple, Emeritus Urological Surgeon, Sheffield Teaching Hospitals NHS Trust

"I believe cymactive has the potential to help urologists, nurses and entire health systems make a real difference to combatting catheter-associated urinary tract infection."

– Prof. Kurt Naber, Technical University of Munich, UTI expert

Ingenion is seeking up to £2m to fund commercialisation.

Are you the right investor?

This raise is specifically for Investors who understand early-stage medtech.

If you are:

- Interested in healthcare and medical devices
- Looking for UK-based investment opportunities with strong IP
- Seeking exits via trade sale, licensing or NHS adoption
- A certified Sophisticated or HNW investor

...then this conversation is worth having.

Have a question? Get an answer – instantly

Talk to Ingenion's remarkable AI Assistant - it knows this opportunity better than any brochure or junior team member. Ask it anything:

"Why should I invest in Ingenion now?"

"How does cymactive™ reduce CAUTIs?"

"What are the exit comparables?"

Visit: ingenion.approvedinvestors.co.uk

Scan QR Code:

